The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer. Taylor Goodstein, MD, and Pretesh Patel, MD, explore how image ...

Urology Times Urologists in Cancer Care | Journal | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

Dornier single-use ureteroscope and ureteral access sheath launch on US market ...

Prostate Cancer | Clinical | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

In this debut episode of The UroOnc Minute, host Adam Weiner, MD, a urologic oncologist and surgeon-scientist at Cedars-Sinai Medical Center, introduces listeners to a new Urology Times podcast ...

In this K-Cast video series, Neal Shore, MD, describes current standards in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and provides an overview of data from the PROfound ...

An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, ...

Live Events | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

The phase 3 PRESTO trial (NCT03009981) assessed combined androgen signaling blockade for a finite treatment period of 52 weeks in patients with high-risk biochemically relapsed prostate cancer. In ...

Petros Grivas, MD, PhD, touches on the signficance of KEYNOTE-905 data, which were presented at ESMO 2025. Data from the KEYNOTE-905 trial (NCT03924895) showed that perioperative enfortumab vedotin ...

A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...